A very small human histology study found changes in sampled adipocytes and reduced average cell cross-sectional area after a HIFEM-plus-RF course; those findings do not quantify an individual’s long-term fat loss.
Keep the two biopsy studies distinct
This cell-size study used three treatments and assessed tissue at one week and one month. The separate 2024 apoptosis study sampled at eight and twenty-four hours after one treatment. They should not be presented as one continuous experiment.
Study at a glance
Design: Very small active-versus-sham human histology study.
Participants: Four active participants and one sham participant.
Research protocol: Three weekly 30-minute abdominal HIFEM+RF sessions.
Follow-up: One week and one month after the course.
Evidence visual: Cell area is not cell diameter
A schematic mathematical illustration, not patient microscopy.
Baseline
Area index: 100 indexed cell area.
Illustrative baseline area set to 100. Circle diameter is proportional to the square root of area.
One week
Area index: 66.5 indexed cell area.
A 33.5% mean cross-sectional-area reduction leaves an index of 66.5. Not 33.5% of body fat removed.
One month
Area index: 68.3 indexed cell area.
A 31.7% mean cross-sectional-area reduction leaves an index of 68.3. Four active participants, one sham.
Source for the visual: [S10]. Only circle area is scaled to the published relative measurement. It is not a real scan, a cell-count result or an individual outcome.
From an early marker to later tissue observations
The early apoptosis study examined a marker during the first day after treatment. A separate histological study looked at sampled fat tissue one week and one month after a treatment course. The two reports therefore address different parts of the biological picture. [S09, S10]
The later-tissue study is interesting because it examined cell shape and size under a microscope rather than relying only on surface appearance. It was also extremely small, so the results must remain attached to that scale of evidence.
Its value is explanatory: it offers observations about what was present in sampled tissue after treatment. It does not create a personal calculation of how much fat will be lost.
For treatment background, read What is EMSCULPT NEO?. This article focuses on the specific research question.
How the study was performed
Four participants received three weekly, 30-minute abdominal treatments combining RF and HIFEM. One additional participant received sham treatment. Punch-biopsy samples were taken at baseline, one week after the course and one month after the course. The tissue was processed and examined histologically. [S10]
The researchers assessed the cross-sectional area of adipocytes, the cells that store fat, as well as their microscopic appearance. The study also collected other observations, but its distinctive contribution was the tissue examination.
Five people, including only one sham participant, cannot establish a broad clinical success rate. A large number of microscopic images from those participants does not turn the study into a large patient trial.
What changed in the tissue samples?
The active-treatment samples showed smaller, altered adipocytes and microscopic changes the authors interpreted as consistent with programmed cell death. Average adipocyte cross-sectional area was 33.5% lower at one week and 31.7% lower at one month. The sham samples did not show comparable treatment-related changes. [S10]
These numbers refer to cell area measured in tissue sections. They are not the percentage decrease in the thickness of the abdominal fat layer, total abdominal fat volume or body weight.
The accompanying visual makes that distinction concrete by using labelled, schematic circles. It does not reproduce real microscopy or imply that every cell or patient behaves identically.
Area is not the same as diameter
This is a small mathematical distinction with a large visual consequence. If a circle's area decreases by one third, its diameter does not decrease by one third. Area changes with the square of radius.
The schematic in this article scales its circles by the square root of the remaining area. A baseline area of 100 becomes 66.5 at one week and 68.3 at one month. Those indexed values illustrate the published area changes; they are not measurements of a particular patient's cells.
A graphic that shrank the diameter by 33.5% would exaggerate the area change. The point of the animation is to teach the measurement, not to make the result look more dramatic.
Does a smaller cell mean that all fat cells were removed?
No. A change in average cell area and evidence of altered cellular morphology are not interchangeable with a direct count showing that all fat cells in the treated region have been removed.
The study discusses both shrinkage and changes consistent with cell death, but the percentages highlighted here are area measurements. They should not be relabelled as “one third of all fat cells permanently deleted”. [S10]
This is why the research question needs to stay visible. A tissue sample can help explore a mechanism, while an imaging study can quantify a local anatomical endpoint. Neither automatically measures every cell in a treated region or establishes an individual's permanent future contour.
Why the one-week and one-month values differ
The study reported similar reductions in mean cell area at the two follow-up points. The small difference between 33.5% and 31.7% should not be interpreted as a validated pattern of fat “returning” or as evidence that another session is required at a particular date. [S10]
These are aggregate observations in a very small biopsy study. They are not a maintenance algorithm. Individual treatment decisions should not be built from a microscopic average alone.
The appropriate interpretation is that tissue changes were documented during the observed post-course period, while broader questions of magnitude and durability require other forms of evidence.
Connecting the biological explanation to a patient decision
Understanding a mechanism can make a consultation more informative, but it should not replace a discussion about the outcome that matters. A patient is usually deciding about appearance, comfort, function or another personally meaningful concern, not about achieving a particular microscope image.
For ¹EM, the useful approach is to connect the biological explanation to the correct level of evidence. This paper supports a discussion of observed cellular changes. The abdominal and area-specific imaging papers address different anatomical outcomes. A clinical assessment then determines whether those outcomes are relevant to the individual.
A treatment plan should not use the biopsy result to promise a clothing size, a fixed fat-loss percentage or a lifelong outcome. It should explain what is known and how the patient's own progress will be assessed.
Safety and commercial context
The study reported transient muscle soreness and redness, without adverse events classified as such by the investigators. A BTL research grant was reported. Those details should accompany the findings rather than being replaced by a blanket claim of a painless, risk-free procedure. [S10]
RF and magnetic stimulation have device-specific precautions, and screening remains necessary even when a small study reports reassuring tolerability. [G01]
The takeaway is a clear mechanism observation: sampled fat cells showed structural and area changes after the studied course. The study is not a guarantee about how much fat any one person will lose or how long their result will last.
Frequently asked questions
What did the 33.5% figure measure?
It measured the average reduction in adipocyte cross-sectional area in the evaluated tissue sections at one week. It was not a percentage of body fat, abdominal circumference or all cells removed. [S10]
How many people were studied?
Four received active treatment and one received sham. The study is a very small human histology investigation, even though multiple tissue sections were examined. [S10]
Does a 33.5% area reduction mean the cell diameter fell 33.5%?
No. For a circular illustration, diameter scales with the square root of area. The schematic uses that relationship so it does not exaggerate the reported area change.
Does the one-month figure mean I need maintenance then?
No. A small difference between follow-up cell-area averages does not establish a clinical maintenance schedule. The study did not validate such a rule. [S10]
Does this prove permanent fat loss?
No. The 2021 cell-size study examined tissue one week and one month after its three-treatment course. The separate 2024 caspase-3 study sampled tissue eight and 24 hours after one treatment. These are different studies and follow-up periods. Neither establishes a permanent personal contour result or prevents future changes in body composition. [S09, S10]
Sources
[S10] Goldberg DJ. Deletion of adipocytes induced by a novel device simultaneously delivering synchronized radiofrequency and HIFEM: Human histological study. Journal of Cosmetic Dermatology. 20(4):1104–1109. 2021. DOI: 10.1111/jocd.13970. https://onlinelibrary.wiley.com/doi/10.1111/jocd.13970
[S09] Goldberg DJ. Induction of fat apoptosis by a combination of synchronized radiofrequency and HIFEM technology: Human histology study. Journal of Cosmetic Dermatology. 23(3):812–817. 2024. DOI: 10.1111/jocd.16197. https://onlinelibrary.wiley.com/doi/10.1111/jocd.16197
[G01] US Food and Drug Administration. Non-Invasive Body Contouring Technologies. Patient information. 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/non-invasive-body-contouring-technologies
Practical information
Start with an individual assessment
General information cannot determine whether treatment is right for you. Request a private assessment with the ¹EM team.
General educational information, not individual medical advice. Published research findings are not ¹EM patient-outcome data. Suitability, experience and results vary.